UpdatesPress Release (Revised)
FDC posted robust Q4 FY26 results: Revenue surged 18.9% to 585 Cr, and PAT jumped 167.4% to 103 Cr, boosted by strong Export Formulations and API growth, including a US business turnaround.
FDC LimitedFDC · Filed with the exchange
The company also received U.S.
FDA approval for Fluconazole Tablets.
No comments yet. Be the first.